Drugs / OBP-801
OBP-801
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02414516 | Mar 2015 → Jun 2019 | cancer | Oncolys BioPharma Inc | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 8
| Date | Issuer | Release |
|---|---|---|
| 2024-07-22 | Oncolys BioPharma Inc | Regulatory OBP-801 の眼科領域での特許査定に関するお知らせ oncolys.com ↗ |
| 2023-03-30 | Oncolys BioPharma Inc | Results 第 127 回日本眼科学会総会での OBP-801 に関する発表のお知らせ oncolys.com ↗ |
| 2021-07-01 | Oncolys BioPharma Inc | Results PR information oncolys.com ↗ |
| 2020-12-04 | Oncolys BioPharma Inc | Results PR information oncolys.com ↗
この度、京都府立医科大学による緑内障手術後の線維化抑制に関する OBP-801 の研究結果が Scientific Reports 誌に掲載されましたので、お知らせいたします。 |
| 2015-03-20 | Oncolys BioPharma Inc | Results 管理担当兼経理部 長 oncolys.com ↗ |
| 2014-12-22 | Oncolys BioPharma Inc | Regulatory 管理担当兼経理部長 六反田 靖 oncolys.com ↗ |
| 2014-12-22 | Oncolys BioPharma Inc | Regulatory IND approval for Phase I clinical trials in the US New epigenetic targeting cancer drug OBP-801 oncolys.com ↗
Oncolys BioPharma Inc. (Oncolys) receives IND (Investigational New Drug) approval for the Phase 1 clinical study on OBP-801, novel epig enetic cancer drug from the US FDA (Food and Drug Administration), which IND application has been filed on November 21st, 2014. |
| 2014-11-25 | Oncolys BioPharma Inc | Regulatory 管理担当兼経理部長 六反田 靖 oncolys.com ↗ |
All press releases naming this drug 9 releases
| Date | Issuer | Release |
|---|---|---|
| 2024-07-22 | Oncolys BioPharma Inc | OBP-801 の眼科領域での特許査定に関するお知らせ oncolys.com ↗ |
| 2023-09-19 | Oncolys BioPharma Inc | OBP-801 の特許査定に関するお知らせ oncolys.com ↗ |
| 2023-03-30 | Oncolys BioPharma Inc | 第 127 回日本眼科学会総会での OBP-801 に関する発表のお知らせ oncolys.com ↗ |
| 2021-07-01 | Oncolys BioPharma Inc | PR information oncolys.com ↗ |
| 2020-12-04 | Oncolys BioPharma Inc | PR information oncolys.com ↗ |
| 2015-03-20 | Oncolys BioPharma Inc | 管理担当兼経理部 長 oncolys.com ↗ |
| 2014-12-22 | Oncolys BioPharma Inc | 管理担当兼経理部長 六反田 靖 oncolys.com ↗ |
| 2014-12-22 | Oncolys BioPharma Inc | IND approval for Phase I clinical trials in the US New epigenetic targeting cancer drug OBP-801 oncolys.com ↗ |
| 2014-11-25 | Oncolys BioPharma Inc | 管理担当兼経理部長 六反田 靖 oncolys.com ↗ |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OBP-801 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02414516 ↗ |
| Known as | Spiruchostatin a | ChEMBL registry synonym — accepted as the source's own label CHEMBL3126832 ↗ |
| Known as | YM-753 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3126832 ↗ |
| Action | Inhibit | “OBP-801, a cyclic depsipeptide class I HDAC inhibitor” PMID 34613570 ↗ Oct 2021 |
| Modality | Small molecule | — CHEMBL3126832 ↗ |
| Route | Intravenous | “OBP-801 will be administered IV” NCT02414516 ↗ |